Depression ‐ not measured · patients with chronic kidney disease (CKD) pruritus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk for at least one adverse event per patient · patients with chronic kidney disease (CKD) pruritus
1 finding from 1 review
Total nocturnal sleep time (minutes) · sleep disturbances in dementia
1 finding from 1 review
Consolidated sleep ‐ not measured · sleep disturbances in dementia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Sleep efficiency · sleep disturbances in dementia
1 finding from 1 review
Total wake time at night (minutes) · sleep disturbances in dementia
1 finding from 1 review
Number of nocturnal awakenings · sleep disturbances in dementia
1 finding from 1 review
Sleep onset latency ‐ not reported · sleep disturbances in dementia
1 finding from 1 review
Adverse events · sleep disturbances in dementia
1 finding from 1 review
Incidence of hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
Summary of findings: Ursodeoxycholic acid may leads to lower incidence of hepatic veno‐occlusive disease ( compared with placebo or no treatment (low certainty).
1 finding from 1 review
Overall survival ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
Summary of findings: Ursodeoxycholic acid showed no clear difference in overall survival ( compared with placebo or no treatment (low certainty).
1 finding from 1 review
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
Summary of findings: Ursodeoxycholic acid may leads to lower all‐cause mortality at 100 days post‐transplant ( compared with placebo or no treatment (low certainty).
1 finding from 1 review
Mortality attributable to hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Ursodeoxycholic acid changes mortality attributable to hepatic veno‐occlusive disease ( compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Quality of life · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of adverse events ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Ursodeoxycholic acid changes frequency of adverse events ( compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Knowledge · patients taking prescribed and over‐the‐counter medications or their carers
1 finding from 1 review
Compliance with medication · patients taking prescribed and over‐the‐counter medications or their carers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health outcomes ‐ not measured · patients taking prescribed and over‐the‐counter medications or their carers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Medication side effects ‐ not measured · patients taking prescribed and over‐the‐counter medications or their carers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not measured · patients taking prescribed and over‐the‐counter medications or their carers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found